Studies looking at the effect of the diabetes drug metformin on prostate cancer (PCa) development and outcomes have yielded conflicting results. For example, two studies published recently reached different conclusions. 

A study by a Canadian research team found that increased cumulative metformin use after a PCa diagnosis was associated with a significantly decreased risk of cancer-specific and all-cause mortality, whereas a team at Mayo Clinic found no significant effect of metformin use on the risk of biochemical recurrence, systemic progression, and all-cause mortality and no significant effect on pathologic findings. 

Renal & Urology News would like to know if urologists believe the evidence supports the use of metformin in PCa patients, so please answer the following poll question.

Continue Reading